The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate (ADC) MYTX-011 in subjects with non-small cell lung cancer.
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Axelia Oncology (Inst); Black Diamond Therapeutics (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EcoR1 Capital (Inst); Editas Medicine (Inst); Eisai (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Molecular Axiom (Inst); Novartis (Inst); Oncorus (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); SeaGen (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); VBL Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EQRx (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunitas (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
George R. Blumenschein
Employment - Janssen (I); johnon & Johnson (I)
Stock and Other Ownership Interests - Virogin Biotech
Consulting or Advisory Role - Abbvie; Adicet Bio; Amgen; ARIAD; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Clovis Oncology; CytomX Therapeutics; Daiichi Sankyo, INC; Genentech; Genzyme; Gilead Sciences; Instil Bio; InterVenn Biosciences; Janssen Oncology; Johnson & Johnson (I); Lilly; Maverick Therapeutics; MedImmune; Merck; Novartis; Novartis; Onconova Therapeutics; Regeneron; Roche; Sanofi; Seagen; Tyme; Virogin Biotech; Xcovery
Research Funding - Adaptimmune; Amgen; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; CytomX Therapeutics; Daiichi Sankyo INC; Duality Biologics; Exelixis; Genentech; GlaxoSmithKline; Immatics; Immunocore; Incyte; Kite, a Gilead company; Macrogenics; MedImmune; Merck; Mythic Therapeutics; Novartis; Regeneron; Repertoire Immune Medicines; Roche; Tmunity Therapeutics, Inc.; Torque; Verastem; Xcovery
 
Timothy F. Burns
Consulting or Advisory Role - Advarra; Amgen; AstraZeneca; Blueprint Medicines; EMD Serono; Janssen Scientific Affairs; Jazz Pharmaceuticals; Mirati Therapeutics; Takeda
Speakers' Bureau - Amgen
 
Jonathan Robert Thompson
Speakers' Bureau - AstraZeneca
 
Amit Deshpande
Employment - Mythic Therapeutics; Nuvalent, Inc.; Rubius Therapeutics (I)
Stock and Other Ownership Interests - Nuvalent, Inc.; Rubius Therapeutics (I)
Patents, Royalties, Other Intellectual Property - development of translational biomarkers in support of NVL-520, a ROS1 inhibitor
Travel, Accommodations, Expenses - Mythic Therapeutics
 
William C Comb
Employment - Mythic Therapeutics
Stock and Other Ownership Interests - Axcella Health
Patents, Royalties, Other Intellectual Property - Axcella Health
 
Brian Fiske
Employment - Bristol-Myers Squibb (Mexico) (I); Mythic Therapeutics
Leadership - Mythic Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb (I); Merck Sharp & Dohme; Mythic Therapeutics
Patents, Royalties, Other Intellectual Property - Mythic Therapeutics
 
Gilles Gallant
Employment - Daiichi Sankyo; Mythic Therapeutics
Leadership - Mythic Therapeutics
Stock and Other Ownership Interests - Abbvie; Amgen; BioMarin; Bristol-Myers Squibb; Johnson & Johnson/Janssen; Merck; Novartis; Pfizer
 
Rebecca Suk Heist
Consulting or Advisory Role - Abbvie; Claim Therapeutics; Daichii Sankyo; Daichii Sankyo; EMD Serono/Merck; EMD Serono/Merck; Lilly; Novartis; Regeneron; Sanofi
Research Funding - Abbvie (Inst); Agios (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Exelixis (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)